Featured,Trends & Articles Jaden Smith Describe His Experience With Psychedelics By Dennis Mutua November 15, 2021 American actor and rapper Jaden Smith has openly shared his experience with psychedelic substances and the healing properties they possess when it comes to mental health. Jaden made this revelation last week during a red talk tabl...
Psychedelic Stocks,Trends & Articles Study Establishes Psilocybin Increases Cognitive and Neural Flexibility in MDD Patients By Dennis Mutua November 12, 2021 According to a recently conducted study and published on Translational Psychiatric, psilocybin-assisted psychotherapy proved to boost both cognitive and neural flexibility in patients suffering from major depressive disorder (MDD)...
Featured,Trends & Articles Naropa University Introduces a Certificate Course in Psychedelic-Assisted Therapies By Dennis Mutua November 11, 2021 Colorado based Naropa University has unveiled a new certificate course in psychedelic-assisted therapies making it to the list of the few learning institutions across the world offering courses combining academic and clinical prac...
Psychedelic Stocks,Trends & Articles Diamond Therapeutics Conducts First Ever Clinical Trial on Low-Dose Psilocybin By Dennis Mutua November 09, 2021 Psychedelic pharmaceutical company focusing on development of drugs to tackle mental conditions Diamond Therapeutics Inc. announced having conducted the first ever clinical trial evaluating low-dose non-hallucinogenic psilocybin. ...
Psychedelic Stocks,Trends & Articles Fluence Raises Funds to Cater for Psychedelic Therapy Training By Dennis Mutua November 05, 2021 Psychedelics educational platform giving professional training and certification in psychedelic therapy and psychedelic integration for healthcare workers Fluence announced having closed an investment round aimed at raising funds ...
Spotlight Stock,Trends & Articles COMPASS Pathways Unveils Phase 2 Trial of its Psilocybin Therapy for PTSD By Dennis Mutua November 04, 2021 Mental healthcare company focusing on making psychedelic therapies for mental health patients COMPASS Pathways Plc. (NASDAQ: CMPS) announced having launched a phase 2 clinical trial of its COMP360 psilocybin therapy in treatment o...
Featured,Trends & Articles U.S FDA Approves First Ever Psilocin Clinical Trial By Dennis Mutua November 03, 2021 Psychedelic company engaging psychedelic drug discovery and extraction to treat mental conditions Filament Health Corp. (NEO: FH) (OTCQB: FLHLF) announced having received an approval from the U.S Food and Drug Administration (FDA)...
Spotlight Stock,Trends & Articles Algernon Pharmaceuticals Sets 6 Hours as Optimal Treatment Period for DMT By Dennis Mutua November 02, 2021 Clinical stage drug re-purposing company specializing on investigating areas of inflammatory bowel disease (IRD), nonalcoholic steatohepatitis (NASH) and chronic kidney disease (CKD) Algernon Pharmaceuticals Inc. (CSE: CSE) (OTCMK...